摘要
目的 讨论曲美他嗪与阿托伐他汀联合治疗冠心病的临床价值。方法 2020年3月至2021年5月期间，本次调查共纳入了68例冠心病患者，采取计算机表法的方式将其划分成两组，每组34例，当中对照组接受阿托伐他汀疗法，另一组则采取曲美他嗪结合阿托伐他汀钙疗法，以评估两组的治疗疗效。结果 经过诊断，我们观察到，在该项调查中，患者的左室射血分数显著增加，而且其左室收缩和舒张的末端比对照组小。患者的血脂水平也显著降低，而且其临床有效性也显著提升。患者的心电图有效性也显著提升，而且其心血管疾病的发病率也显著降低，差异呈现P<0.05。结论 曲美他嗪与阿托伐他汀联合治疗冠心病的效果确切，可改善患者的心功能指标，优化血脂指标，值得临床推广应用。
关键词： 冠心病；曲美他嗪；阿托伐他汀；心功能
Abstract
Objective: To discuss the clinical value of trimetazidine combined with atorvastatin in the treatment of coronary heart disease. Methods: From March 2020 to May 2021, a total of 68 patients with coronary heart disease were enrolled in this study and divided into two groups with 34 patients in each group by computer table method. The control group received atorvastatin therapy and the other group received trimetazidine combined with atorvastatin calcium therapy to evaluate the therapeutic efficacy of the two groups. Results: After diagnosis, we observed a significant increase in left ventricular ejection fraction in this study and a smaller left ventricular systolic and diastolic end than in the control group. Patients also had significantly lower blood lipid levels, and its clinical effectiveness was significantly improved. The ECG effectiveness of patients was also significantly improved, and the incidence of cardiovascular disease was also significantly reduced, the difference was P<0.05. Conclusion : The combination of trimetazidine and atorvastatin in the treatment of coronary heart disease is effective, can improve cardiac function indicators and optimize blood lipid indicators in patients with coronary heart disease, and is worthy of clinical promotion and application.
Key words： Coronary heart disease; Trimetazidine; Atorvastatin; Cardiac function
参考文献 References
[1] 张红梅.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床效果[J].临床合理用药杂志,2022, 15(28): 53-55.
[2] 吴玉红.阿托伐他汀钙联合曲美他嗪治疗冠心病的疗效[J].中国城乡企业卫生,2022,37(08):151-152.
[3] 王慧,毕艺.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床疗效及安全性[J].当代医学,2022,28(20):125-127.
[4] 丁凡.曲美他嗪联合阿托伐他汀钙用于冠心病心绞痛伴血脂异常的治疗效果[J].慢性病学杂志,2022, 23(07): 1089-1092.
[5] Zhang L, Chen W, Gan D. Analysis of the physiological and pathological factors of hospitalized patients taking warfarin and the correlation between drug interactions and warfarin efficacy. Ann Palliat Med. 2021 May;10(5): 5400-5406.
[6] 李慕成.老年冠心病运用阿托伐他汀钙复合曲美他嗪的临床诊治效果分析[J].医学食疗与健康,2022, 20(02): 69-72.
[7] 杨琛.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常患者的临床效果[J].中国医药指南,2022, 20(02): 99-101.
[8] 唐天伟.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的效果研究[J].中国实用医药,2021, 16(31): 117-120.
[9] 张小芳.阿托伐他汀钙联合曲美他嗪治疗老年冠心病患者的临床效果观察[J].中国实用医药,2021, 16(29): 141-143.
[10] 党海鹤.曲美他嗪联合阿托伐他汀钙治疗冠心病后患者的心电图变化[J].临床医学研究与实践,2021,6(26): 68-70.
[11] Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, Widimský P, Danchin N; ATPCI investigators. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double- blind, placebo-controlled trial. Lancet. 2020 Sep 19;396 (10254):830-838.
[12] 张维新.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究[J].黑龙江中医药, 2021, 50(02): 408-409.
[13] 王艳.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛的临床疗效观察[J].黑龙江科学,2021,12(12):54-55.